Literature DB >> 22509006

Amorfrutins are potent antidiabetic dietary natural products.

Christopher Weidner1, Jens C de Groot, Aman Prasad, Anja Freiwald, Claudia Quedenau, Magdalena Kliem, Annabell Witzke, Vitam Kodelja, Chung-Ting Han, Sascha Giegold, Matthias Baumann, Bert Klebl, Karsten Siems, Lutz Müller-Kuhrt, Annette Schürmann, Rita Schüler, Andreas F H Pfeiffer, Frank C Schroeder, Konrad Büssow, Sascha Sauer.   

Abstract

Given worldwide increases in the incidence of obesity and type 2 diabetes, new strategies for preventing and treating metabolic diseases are needed. The nuclear receptor PPARγ (peroxisome proliferator-activated receptor gamma) plays a central role in lipid and glucose metabolism; however, current PPARγ-targeting drugs are characterized by undesirable side effects. Natural products from edible biomaterial provide a structurally diverse resource to alleviate complex disorders via tailored nutritional intervention. We identified a family of natural products, the amorfrutins, from edible parts of two legumes, Glycyrrhiza foetida and Amorpha fruticosa, as structurally new and powerful antidiabetics with unprecedented effects for a dietary molecule. Amorfrutins bind to and activate PPARγ, which results in selective gene expression and physiological profiles markedly different from activation by current synthetic PPARγ drugs. In diet-induced obese and db/db mice, amorfrutin treatment strongly improves insulin resistance and other metabolic and inflammatory parameters without concomitant increase of fat storage or other unwanted side effects such as hepatoxicity. These results show that selective PPARγ-activation by diet-derived ligands may constitute a promising approach to combat metabolic disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22509006      PMCID: PMC3358853          DOI: 10.1073/pnas.1116971109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  Principles for modulation of the nuclear receptor superfamily.

Authors:  Hinrich Gronemeyer; Jan-Ake Gustafsson; Vincent Laudet
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

Review 2.  The many faces of PPARgamma.

Authors:  Michael Lehrke; Mitchell A Lazar
Journal:  Cell       Date:  2005-12-16       Impact factor: 41.582

Review 3.  PPARs and other nuclear receptors in inflammation.

Authors:  Giovanni Rizzo; Stefano Fiorucci
Journal:  Curr Opin Pharmacol       Date:  2006-06-13       Impact factor: 5.547

4.  Diabetes and obesity: the twin epidemics.

Authors:  Simon Smyth; Andrew Heron
Journal:  Nat Med       Date:  2006-01       Impact factor: 53.440

5.  Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.

Authors:  Michael Schupp; Markus Clemenz; Romain Gineste; Henning Witt; Jürgen Janke; Stephane Helleboid; Nathalie Hennuyer; Patricia Ruiz; Thomas Unger; Bart Staels; Ulrich Kintscher
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

6.  Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development.

Authors:  B M Spiegelman; M Frank; H Green
Journal:  J Biol Chem       Date:  1983-08-25       Impact factor: 5.157

Review 7.  Peroxisome proliferator-activated receptor gamma: the more the merrier?

Authors:  C A Argmann; T-A Cock; J Auwerx
Journal:  Eur J Clin Invest       Date:  2005-02       Impact factor: 4.686

Review 8.  Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome.

Authors:  Tom Hsun-Wei Huang; Bhavani Prasad Kota; Valentina Razmovski; Basil D Roufogalis
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-01       Impact factor: 4.080

9.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.

Authors:  R T Nolte; G B Wisely; S Westin; J E Cobb; M H Lambert; R Kurokawa; M G Rosenfeld; T M Willson; C K Glass; M V Milburn
Journal:  Nature       Date:  1998-09-10       Impact factor: 49.962

10.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

View more
  54 in total

1.  Naturally improving insulin resistance with amorfrutins.

Authors:  Philippe Lefebvre; Bart Staels
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-27       Impact factor: 11.205

2.  Neutral Loss Scan - Based Strategy for Integrated Identification of Amorfrutin Derivatives, New Peroxisome Proliferator-Activated Receptor Gamma Agonists, from Amorpha Fruticosa by UPLC-QqQ-MS/MS and UPLC-Q-TOF-MS.

Authors:  Chu Chen; Ying Xue; Qing-Miao Li; Yan Wu; Jian Liang; Lin-Sen Qing
Journal:  J Am Soc Mass Spectrom       Date:  2018-02-05       Impact factor: 3.109

3.  A photocleavable masked nuclear-receptor ligand enables temporal control of C. elegans development.

Authors:  Joshua C Judkins; Parag Mahanti; Jacob B Hoffman; Isaiah Yim; Adam Antebi; Frank C Schroeder
Journal:  Angew Chem Int Ed Engl       Date:  2014-01-22       Impact factor: 15.336

4.  Protein sets define disease states and predict in vivo effects of drug treatment.

Authors:  David Meierhofer; Christopher Weidner; Ludger Hartmann; Johannes A Mayr; Chung-Ting Han; Frank C Schroeder; Sascha Sauer
Journal:  Mol Cell Proteomics       Date:  2013-04-11       Impact factor: 5.911

5.  Resveratrol and its metabolites bind to PPARs.

Authors:  E Calleri; G Pochetti; K S S Dossou; A Laghezza; R Montanari; D Capelli; E Prada; F Loiodice; G Massolini; M Bernier; R Moaddel
Journal:  Chembiochem       Date:  2014-05-05       Impact factor: 3.164

Review 6.  Minireview: Challenges and opportunities in development of PPAR agonists.

Authors:  Matthew B Wright; Michele Bortolini; Moh Tadayyon; Martin Bopst
Journal:  Mol Endocrinol       Date:  2014-08-22

7.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

Review 8.  Antidiabetic plant-derived nutraceuticals: a critical review.

Authors:  Jayapal Naveen; Vallikannan Baskaran
Journal:  Eur J Nutr       Date:  2017-10-11       Impact factor: 5.614

9.  Aspirin's Active Metabolite Salicylic Acid Targets High Mobility Group Box 1 to Modulate Inflammatory Responses.

Authors:  Hyong Woo Choi; Miaoying Tian; Fei Song; Emilie Venereau; Alessandro Preti; Sang-Wook Park; Keith Hamilton; G V T Swapna; Murli Manohar; Magali Moreau; Alessandra Agresti; Andrea Gorzanelli; Francesco De Marchis; Huang Wang; Marc Antonyak; Robert J Micikas; Daniel R Gentile; Richard A Cerione; Frank C Schroeder; Gaetano T Montelione; Marco E Bianchi; Daniel F Klessig
Journal:  Mol Med       Date:  2015-06-18       Impact factor: 6.354

10.  Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARγ) agonist with potent glucose-lowering properties.

Authors:  C Weidner; S J Wowro; A Freiwald; K Kawamoto; A Witzke; M Kliem; K Siems; L Müller-Kuhrt; F C Schroeder; S Sauer
Journal:  Diabetologia       Date:  2013-05-18       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.